Inovio Pharmaceuticals, Inc.
GBMB.F
Frankfurt Stock Exchange0.55
EUR
+0.02
- -
ISIN
US45773H4092
Return %
Stock
S&P500
1Y
-96.36
26.53
3Y
-99.52
76.60
5Y
-98.58
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jacqueline E. Shea
- Full Time Employees
- 184
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 660 West Germantown Pike Plymouth Meeting PA United States of America 19462
- IPO Date
- Apr 7, 2005
- Website
- inovio.com
- Similar Companies
- Business
- Inovio Pharmaceuticals, Inc. (NASDAQ: INO; FSE: GBMB) is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize DNA medicines for HPV-related diseases, cancer and infectious diseases; its proprietary platform utilizes precisely designed DNA plasmids delivered via investigational CELLECTRA devices to enable cells to produce proteins targeting disease without chemical adjuvants, lipid nanoparticles or viral vectors. Core products in its pipeline include INO-3107, a lead candidate for recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11; VGX-3100 for HPV-related cervical, anal or perianal high-grade squamous intraepithelial lesions (HSIL); INO-3112 for HPV-related oropharyngeal squamous cell carcinoma (OPSCC); INO-5401 for glioblastoma multiforme (GBM) and cancer prevention in BRCA1/2 mutation carriers; INO-4201 for Ebola; as well as emerging DNA-encoded monoclonal antibody (DMAb) and DNA protein (DPROT) technologies. Founded in 1983 and headquartered in Plymouth Meeting, Pennsylvania, the company operates primarily in the United States with international clinical collaborations and serves healthcare providers, patients and partners in North America, Europe and Asia. Recent developments include positive Phase 2/3 durability data for INO-3107 showing 50% complete response in RRP patients at two years with sustained benefits into year three; U.K. Innovative Licensing and Access Pathway (ILAP) designation for INO-3107; a 2024 clinical collaboration and supply agreement with Coherus BioSciences for INO-3112 combined with LOQTORZI in high-risk OPSCC; plans to submit a biologics license application (BLA) for INO-3107 by mid-2025 and achieve commercial readiness by year-end; a $25 million public offering priced in July 2025 to fund operations; and publication of proof-of-concept data on DMAb technology in Nature Medicine alongside preclinical advancements in DPROT for hemophilia.